2,3-dihydro-6-methoxy-2-phenyl-1H-inden-1-one | 108840-75-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: 2,3-dihydro-6-methoxy-2-phenyl-1H-inden-1-one
• 英文别名: 6-methoxy-2-phenyl-2,3-dihydro-1H-inden-1-one；6-Methoxy-2-phenyl-indan-1-on；6-Methoxy-2-phenyl-indanon-(1)；6-methoxy-2-phenylindan-1-one；6-methoxy-2-phenyl-1-indanone；6-methoxy-2-phenyl-2,3-dihydroinden-1-one
• CAS: 108840-75-1
• 化学式: C₁₆H₁₄O₂
• 分子量: 238.286
• InChiKey: YBEKWYDXPKZQBO-UHFFFAOYSA-N

物化性质

• 沸点：
  383.2±41.0 °C(Predicted)
• 密度：
  1.172±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2,3-dihydro-6-methoxy-2-phenyl-1H-inden-1-one 在 5% Pd on active carbon 、 钴 氨 、 氢气 、 三乙胺 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 乙醇 、 正己烷 为溶剂， -78.0~40.0 ℃ 、400.0 kPa 条件下， 反应 0.33h， 生成 6-Methoxy-2-phenyl-1-[2-(trifluoroacetylamino)ethyl]indan
  参考文献：
  名称：

  Synthesis of a Novel Series of Benzocycloalkene Derivatives as Melatonin Receptor Agonists

  摘要：

  We synthesized a novel series of benzocycloalkene derivatives and evaluated their binding affinities to melatonin receptors. To control the spatial position of the amide group, one of the important pharmacophores, we incorporated an endo double bond, an exo double bond (E- and Z-configurations), and a chiral center (R- and S-configurations) at position 1. The indan derivatives with the S-configuration at position 1 were the most promising in terms of potency and selectivity for the human melatonin receptor (MT, site), while compounds with the R-configuration showed little potential. Our next attempt was to investigate the most favorable conformation of the methoxy group, the other important pharmacophore for binding to the MT, receptor. The introduction of a methyl group at position 5 of the indene ring conserved affinity; however, at position 7, it caused a decrease in affinity. These results suggested that the substitution at position 7 forced the methoxy group to adopt an unfavorable orientation. The optimization of the condensed ring size and substituents led to (S)-8d [(S)-N-[2-(2,3-dihydro-6-methoxy-1H-inden-1-yl)ethyl]propionamide], which had high affinity for the human MT3 receptor (K-i = 0.041 nM) but no significant affinity for the hamster MT3 receptor (K-i = 3570 nM). In addition, a practical synthetic method of chiral N-[2-(2,3-dihydro-1H-inden-1-yl)ethyl]-alkanamides employing asymmetric hydrogenation with (S)-2,2'-bis(diphenylphosphino)-1,1'-binaphthyl-Ru has been established.

  DOI：

  10.1021/jm020114g
• 作为产物：
  描述：

  3-(4-methoxyphenyl)-2-phenylacrylic acid 在 sodium hydroxide 、 sodium amalgam 、 磷酸 、 phosphorus pentoxide 作用下， 生成 2,3-dihydro-6-methoxy-2-phenyl-1H-inden-1-one
  参考文献：
  名称：

  2-苯基茚满的一些衍生物

  摘要：

  DOI：

  10.1039/jr9540001640

文献信息

• Benzocycloalkene compounds, their production and use
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US05922771A1

  公开（公告）日：1999-07-13

  A compound of the formula ##STR1## wherein R.sup.1 and R.sup.2 independently represent H or an optionally substituted hydrocarbon group; R.sup.3 represents an optionally substituted hydrocarbon group; R.sup.4 represents H or a hydrocarbon group; ring A represents a substituted benzene ring; X represents a C.sub.2-4 alkylene group etc.; and Y represents a bond or a lower alkylene group, or salts thereof is useful as prophylactic or therapeutic agents of diseases related with melatonin activity.

  式##STR1##中的化合物，其中R.sup.1和R.sup.2分别代表H或一个可选择取代的碳氢基团；R.sup.3代表一个可选择取代的碳氢基团；R.sup.4代表H或一个碳氢基团；环A代表一个取代的苯环；X代表一个C.sub.2-4烷基基团等；Y代表键或一个较低的烷基基团，或其盐，可用作与褪黑激素活性相关的疾病的预防或治疗剂。
• [EN] INDANONE AND INDANDIONE DERIVATIVES AND HETEROCYCLIC ANALOGS<br/>[FR] DÉRIVÉS D'INDANONE ET D'INDANEDIONE ET ANALOGUES HÉTÉROCYCLIQUES
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2013068785A1

  公开（公告）日：2013-05-16

  The invention relates to indanone/indandione derivatives and heterocyclic analogs of Formula (I) wherein Ar1, A, B, L1, Y, Z, and (R1)n n are as described in the description; to pharmaceutically acceptable salts thereof, and to the use of such compounds as medicaments, especially as NPS receptor antagonists.

  这项发明涉及吲哚酮/吲哚二酮衍生物和式（I）中的杂环类似物，其中Ar1、A、B、L1、Y、Z和（R1）n n如描述中所述；其药学上可接受的盐，以及将这些化合物用作药物，特别是作为NPS受体拮抗剂。
• Imidazole derivatives
  申请人：——

  公开号：US20010056109A1

  公开（公告）日：2001-12-27

  An imidazole derivative of formula (I) 1 or a pharmaceutically acceptable salt or derivative thereof. The compounds of formula I exhibit affinity for alpha2 adrenoceptors.

  公式(I)的咪唑衍生物或其药用可接受的盐或衍生物。公式I的化合物具有对α2肾上腺素受体的亲和力。
• [EN] PYRIDINE DERIVATIVES USEFUL FOR INHIBITING SODIUM/CALCIUM EXCHANGE SYSTEM<br/>[FR] DERIVES PYRIDINE SERVANT A INHIBER LE SYSTEME D'ECHANGE SODIUM/CALCIUM
  申请人：ORION CORP

  公开号：WO2004063191A1

  公开（公告）日：2004-07-29

  Therapeutically active compounds of formula (I) or (II) wherein X is -O-, -CH2- or -C(O)-; Z is -CHR12- or a valence bond; Y is -CH2-, -C(O)-, CH(OR13)-, -O-, -S-; provided that in case Z is a valence bond, Y is not C(O); the dashed line representing an optional double bond in which case Z is -CR12- ­and Y is -CH2-, -C(O)- or -CH(OR10)- (in formula II) or -CH- (in formula I); R2 and R3 are independently H, lower alkyl, lower alkoxy, -NO2, halogen, -CF3, -OH, benzyloxy or a group of formula (IIIa). R1 is H, CN, halogen, -CONH2, -COOR15, CH2NR15R18, NHC(O)R5, NHCH2R5, NHR20, NR21R22, NHC(NH)NHCH3 or, in case the compound is of formula (II) wherein the optional double bond exists or in case R2 or R3 is benzyloxy or a group of formula (IIIa) or in case the pyridine ring of formula (I) or (II) is attached to the oxygen atom in 3-, 4- or 5-position, R1 can also be -NO2 or NR16R17; R4 is H, -NO2, CN, halogen, -CONH2, -COOR15, -CH2NR15R18, -NR16R17, NHC(O)R5 or -NHC(NH)NHCH3; R5 is alkyl substituted with 1-3 substituents selected from the group consisting of halogen, amino and hydroxy, or carboxyalkyl, in which the alkyl portion is optionally substituted with 1-3 substituents selected from the group consisting of halogen, amino and hydroxyl, -CHR6NR,R8 or one of the following groups: formula (IVa), (IVb), (IVc), (IVd), (IVe), and pharmaceutically acceptable salts and esters thereof. The compounds are potent inhibitors of Na+/Ca2+ exchange mechanism.

  式（I）或（II）的治疗活性化合物，其中X为-O-，-CH2-或-C（O）-；Z为-CHR12-或一个价键；Y为-CH2-，-C（O）-，CH（OR13）-，-O-，-S-；条件是如果Z为一个价键，则Y不是C（O）；虚线表示可选的双键，此时Z为-CR12-，Y为-CH2-，-C（O）-或-CH（OR10）-（在式（II）中）或-CH-（在式（I）中）；R2和R3独立地为H，较低的烷基，较低的烷氧基，-NO2，卤素，-CF3，-OH，苄氧基或式（IIIa）的基团。R1为H，CN，卤素，-CONH2，-COOR15，CH2NR15R18，NHC（O）R5，NHCH2R5，NHR20，NR21R22，NHC（NH）NHCH3的基团，或者，如果化合物为式（II），其中存在可选的双键，或者如果R2或R3为苄氧基或式（IIIa）的基团，或者如果式（I）或（II）的吡啶环附着在3-，4-或5-位置的氧原子上，则R1也可以是-NO2或NR16R17；R4为H，-NO2，CN，卤素，-CONH2，-COOR15，-CH2NR15R18，-NR16R17，NHC（O）R5或-NHC（NH）NHCH3；R5为烷基，其上取代有1-3个取自卤素、氨基和羟基或羧基的取代基，其中烷基部分可选地取代有1-3个取自卤素、氨基和羟基的取代基，-CHR6NR,R8或以下所示的一个基团之一：式（IVa），（IVb），（IVc），（IVd），（IVe），以及其药用可接受的盐和酯。这些化合物是Na+/Ca2+交换机制的有效抑制剂。
• Rhodium-catalyzed intramolecular hydroacylation of 1,2-disubstituted alkenes for the synthesis of 2-substituted indanones
  作者：Jing Yuan、Chong Liu、Yan Chen、Zhenfeng Zhang、Deyue Yan、Wanbin Zhang

  DOI：10.1016/j.tet.2018.11.057

  日期：2019.1

  The intramolecular hydroacylation of 1,2-disubstituted alkenes was considered to be a challenging task due to the side reactions resulted from the lack of additional substituent at 1-position and the low activity caused by the steric hindrance of substituent at 2-position, and an asymmetric version has not been considered possible due to problems associated with the racemization of the products. We

  1，2-二取代烯烃的分子内加氢酰化被认为是一项艰巨的任务，这是由于在1位缺少额外的取代基以及在2位取代基的空间位阻引起的低活性导致的副反应，以及由于与产品消旋有关的问题，非对称版本尚未被认为是可行的。我们已经部分解决了这些问题。在活化的二膦-Rh配合物的催化下，在选定的二卤代溶剂中反应，邻-（2-芳基乙烯基）苯甲醛的分子内氢酰化反应可提供高产率的相应2-芳基-1-茚满酮，以及使用o的不对称变体-（2-烷基乙烯基）苯甲醛以高收率和中等对映选择性提供手性2-烷基-1-茚满酮。